Emerging data now extend the therapeutic relevance of incretin-based therapies to individuals with established ASCVD and overweight/obesity without diabetes, and HFpEF with obesity, while SGLT2 inhibitors show promise in post-MI and acute HF settings. This evidence concerns the gene SLC5A2 and atherosclerosis.